Literature DB >> 8426482

Establishment of a CD4-positive plasmacytoma cell line (AMO1).

S Shimizu1, T Takiguchi, M Fukutoku, R Yoshioka, Y Hirose, S Fukuhara, H Ohno, Y Isobe, S Konda.   

Abstract

A human plasmacytoma cell line (AMO1) was established. The AMO1 cells had the light and electron microscopic characteristics typical of plasmacytoma cells and did not harbor Epstein-Barr virus. These cells expressed cytoplasmic immunoglobulin A kappa and the immunoglobulin heavy-chain gene (JH) and kappa light-chain gene (C kappa) were rearranged. Coexpression of a CD4 antigen and plasma cell antigens (CD38 and PCA-1) was an unusual and sustained feature. Neither the T-cell receptor beta nor the gamma chain gene displayed the rearranged form. Other lineage-specific surface antigens, namely T, B, monocytoid, and myeloid antigens, were all negative in AMO1. In accordance with the surface CD4 expression, polymerase chain reaction analysis indicated constitutive expression of CD4 mRNA, and the cytogenetic findings revealed that AMO1 cells had a derivative chromosome 12, which had a structural abnormality of the short arm carrying the CD4 gene locus. These findings provide strong evidence for the presence of CD4-positive malignant plasma cells and raise the possibility that the CD4 expression in the AMO1 cell line is closely associated with the derivative chromosome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8426482

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  7 in total

1.  The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.

Authors:  Mélanie Op; Sérgio T Ribeiro; Claire Chavarria; Aude De Gassart; Léa Zaffalon; Fabio Martinon
Journal:  Cell Death Dis       Date:  2022-05-19       Impact factor: 9.685

2.  CD56 expression in human myeloma cells derived from the neurogenic gene expression: possible role of the SRY-HMG box gene, SOX4.

Authors:  Mohd S Iqbal; Ken-ichiro Otsuyama; Karim Shamsasenjan; Hideki Asaoku; Michio M Kawano
Journal:  Int J Hematol       Date:  2010-01-05       Impact factor: 2.490

3.  IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33+ myeloma cells.

Authors:  Karim Shamsasenjan; Ken-Ichiro Otsuyama; Saeid Abroun; Mohd S Iqbal; Maged S Mahmoud; Hideki Asaoku; Michio M Kawano
Journal:  Int J Hematol       Date:  2009-03-04       Impact factor: 2.490

4.  A novel selective small-molecule PI3K inhibitor is effective against human multiple myeloma in vitro and in vivo.

Authors:  J Glauer; N Pletz; M Schön; P Schneider; N Liu; K Ziegelbauer; S Emmert; G G Wulf; M P Schön
Journal:  Blood Cancer J       Date:  2013-09-06       Impact factor: 11.037

5.  The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease.

Authors:  Julia Dotterweich; Robert J Tower; Andreas Brandl; Marc Müller; Lorenz C Hofbauer; Andreas Beilhack; Regina Ebert; Claus C Glüer; Sanjay Tiwari; Norbert Schütze; Franz Jakob
Journal:  PLoS One       Date:  2016-05-09       Impact factor: 3.240

6.  Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells.

Authors:  Miho Nara; Kazuaki Teshima; Atsushi Watanabe; Mitsugu Ito; Keiko Iwamoto; Atsushi Kitabayashi; Masaaki Kume; Yoshiaki Hatano; Naoto Takahashi; Shinsuke Iida; Kenichi Sawada; Hiroyuki Tagawa
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

7.  A flow cytometry assay to quantify intercellular exchange of membrane components.

Authors:  Dimitrios Poulcharidis; Kimberley Belfor; Alexander Kros; Sander I van Kasteren
Journal:  Chem Sci       Date:  2017-05-24       Impact factor: 9.825

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.